ASCL1 and RET Expression Defines a Clinically Relevant Subgroup of Lung Adenocarcinoma Characterized by Neuroendocrine Differentiation

Overview

Journal Oncogene

Specialties Molecular Biology
Oncology

Date 2013 Sep 17

PMID 24037524

Citations 31

Authors

F Kosari

C M Ida

M-C Aubry

L Yang

I V Kovtun

J L S Klein

Y Li

S Erdogan

S C Tomaszek

S J Murphy

L C Bolette

C P Kolbert

P Yang

D A Wigle

G Vasmatzis

Affiliations

Soon will be listed here.

Abstract

ASCL1 is an important regulatory transcription factor in pulmonary neuroendocrine (NE) cell development, but its value as a biomarker of NE differentiation in lung adenocarcinoma (AD) and as a potential prognostic biomarker remains unclear. We examined ASCL1 expression in lung cancer samples of varied histologic subtype, clinical outcome and smoking status and compared with expression of traditional NE markers. ASCL1 mRNA expression was found almost exclusively in smokers with AD, in contrast to non-smokers and other lung cancer subtypes. ASCL1 protein expression by immunohistochemical (IHC) analysis correlated best with synaptophysin compared with chromogranin and CD56/NCAM. Analysis of a compendium of 367 microarray-based gene expression profiles in stage I lung adenocarcinomas identified significantly higher expression levels of the RET oncogene in ASCL1-positive tumors (ASCL1(+)) compared with ASCL1(-) tumors (q-value <10(-9)). High levels of RET expression in ASCL1(+) but not in ASCL1(-) tumors was associated with significantly shorter overall survival (OS) in stage 1 (P=0.007) and in all AD (P=0.037). RET protein expression by IHC had an association with OS in the context of ASCL1 expression. In silico gene set analysis and in vitro experiments by ASCL1 shRNA in AD cells with high endogenous expression of ASCL1 and RET implicated ASCL1 as a potential upstream regulator of the RET oncogene. Also, silencing ASCL1 in AD cells markedly reduced cell growth and motility. These results suggest that ASCL1 and RET expression defines a clinically relevant subgroup of ∼10% of AD characterized by NE differentiation.

Citing Articles

Survival comparison of pulmonary neuroendocrine carcinoma, adenocarcinoma with neuroendocrine differentiation, and adenocarcinoma.

Tai Q, Bao Y, Song N, Hu X, Duan L J Thorac Dis. 2024; 16(1):604-614.

PMID: 38410570 PMC: 10894407. DOI: 10.21037/jtd-23-1811.

Cobind: quantitative analysis of the genomic overlaps.

Ma T, Guo L, Yan H, Wang L Bioinform Adv. 2023; 3(1):vbad104.

PMID: 37600846 PMC: 10438957. DOI: 10.1093/bioadv/vbad104.

Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small-cell lung cancer: an international multicenter study.

Megyesfalvi Z, Barany N, Lantos A, Valko Z, Pipek O, Lang C J Pathol. 2022; 257(5):674-686.

PMID: 35489038 PMC: 9541929. DOI: 10.1002/path.5922.

Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation.

Merkens L, Sailer V, Lessel D, Janzen E, Greimeier S, Kirfel J J Exp Clin Cancer Res. 2022; 41(1):46.

PMID: 35109899 PMC: 8808994. DOI: 10.1186/s13046-022-02255-y.

In-depth molecular analysis of combined and co-primary pulmonary large cell neuroendocrine carcinoma and adenocarcinoma.

Hermans B, Derks J, Hillen L, van der Baan I, van den Broek E, von der Thusen J Int J Cancer. 2021; 150(5):802-815.

PMID: 34674268 PMC: 9298697. DOI: 10.1002/ijc.33853.

References

Arighi E, Borrello M, Sariola H . RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev. 2005; 16(4-5):441-67. DOI: 10.1016/j.cytogfr.2005.05.010. View

Bryant C, Albertus D, Kim S, Chen G, Brambilla C, Guedj M . Clinically relevant characterization of lung adenocarcinoma subtypes based on cellular pathways: an international validation study. PLoS One. 2010; 5(7):e11712. PMC: 2908611. DOI: 10.1371/journal.pone.0011712. View

Khuder S . Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis. Lung Cancer. 2001; 31(2-3):139-48. DOI: 10.1016/s0169-5002(00)00181-1. View

Rheinbay E, Suva M, Gillespie S, Wakimoto H, Patel A, Shahid M . An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma. Cell Rep. 2013; 3(5):1567-79. PMC: 3774301. DOI: 10.1016/j.celrep.2013.04.021. View

Lodish M, Stratakis C . RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer. Expert Rev Anticancer Ther. 2008; 8(4):625-32. PMC: 2670186. DOI: 10.1586/14737140.8.4.625. View

Shaw A, Yeap B, Mino-Kenudson M, Digumarthy S, Costa D, Heist R . Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009; 27(26):4247-53. PMC: 2744268. DOI: 10.1200/JCO.2009.22.6993. View

Kang H, Kim I, Park J, Shin Y, Ku J, Jung M . Identification of genes with differential expression in acquired drug-resistant gastric cancer cells using high-density oligonucleotide microarrays. Clin Cancer Res. 2004; 10(1 Pt 1):272-84. DOI: 10.1158/1078-0432.ccr-1025-3. View

Kageyama R, Nakanishi S . Helix-loop-helix factors in growth and differentiation of the vertebrate nervous system. Curr Opin Genet Dev. 1997; 7(5):659-65. DOI: 10.1016/s0959-437x(97)80014-7. View

Burton M, Kawashima A, Brayer J, Kazemi H, Shannon D, Schuchardt A . RET proto-oncogene is important for the development of respiratory CO2 sensitivity. J Auton Nerv Syst. 1997; 63(3):137-43. DOI: 10.1016/s0165-1838(97)00002-7. View

10.

Huber K, Karch N, Ernsberger U, Goridis C, Unsicker K . The role of Phox2B in chromaffin cell development. Dev Biol. 2005; 279(2):501-8. DOI: 10.1016/j.ydbio.2005.01.007. View

11.

Ionescu D, Treaba D, Gilks C, Leung S, Renouf D, Laskin J . Nonsmall cell lung carcinoma with neuroendocrine differentiation--an entity of no clinical or prognostic significance. Am J Surg Pathol. 2007; 31(1):26-32. DOI: 10.1097/01.pas.0000213319.04919.97. View

12.

Powell C, Spira A, Derti A, DeLisi C, Liu G, Borczuk A . Gene expression in lung adenocarcinomas of smokers and nonsmokers. Am J Respir Cell Mol Biol. 2003; 29(2):157-62. DOI: 10.1165/rcmb.2002-0183RC. View

13.

Poulsen T, Pedersen N, Juel H, Poulsen H . A chimeric fusion of the hASH1 and EZH2 promoters mediates high and specific reporter and suicide gene expression and cytotoxicity in small cell lung cancer cells. Cancer Gene Ther. 2008; 15(9):563-75. DOI: 10.1038/cgt.2008.24. View

14.

Osada H, Tatematsu Y, Yatabe Y, Horio Y, Takahashi T . ASH1 gene is a specific therapeutic target for lung cancers with neuroendocrine features. Cancer Res. 2005; 65(23):10680-5. DOI: 10.1158/0008-5472.CAN-05-1404. View

15.

Landi M, Dracheva T, Rotunno M, Figueroa J, Liu H, Dasgupta A . Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS One. 2008; 3(2):e1651. PMC: 2249927. DOI: 10.1371/journal.pone.0001651. View

16.

Kouvaraki M, Shapiro S, Perrier N, Cote G, Gagel R, Hoff A . RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid. 2005; 15(6):531-44. DOI: 10.1089/thy.2005.15.531. View

17.

Massion P, Zou Y, Chen H, Jiang A, Coulson P, Amos C . Smoking-related genomic signatures in non-small cell lung cancer. Am J Respir Crit Care Med. 2008; 178(11):1164-72. PMC: 2720147. DOI: 10.1164/rccm.200801-142OC. View

18.

Borges M, Linnoila R, van de Velde H, Chen H, Nelkin B, MABRY M . An achaete-scute homologue essential for neuroendocrine differentiation in the lung. Nature. 1997; 386(6627):852-5. DOI: 10.1038/386852a0. View

19.

Fujiwara T, Hiramatsu M, Isagawa T, Ninomiya H, Inamura K, Ishikawa S . ASCL1-coexpression profiling but not single gene expression profiling defines lung adenocarcinomas of neuroendocrine nature with poor prognosis. Lung Cancer. 2011; 75(1):119-25. DOI: 10.1016/j.lungcan.2011.05.028. View

20.

Boldrini L, Ali G, Gisfredi S, Ursino S, Baldini E, Melfi F . Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: a population-based prospective study. Oncol Rep. 2009; 22(4):683-91. DOI: 10.3892/or_00000488. View